Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital.
Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
Ageing causes stem cells to lose their normal structure by increased activity of the protein CDC42. Normalising CDC42 activity can restore structure, order and functionality in those aged stem cells.
Comments are closed.